Literature DB >> 22174067

Malaria therapy in HIV: drug interactions between nevirapine and quinine.

A Uriel1, P Lewthwaite.   

Abstract

We report the case of an HIV-positive Nigerian man on antiretroviral therapy (ART) with an undetectable viral load who presented with rigors, fever and back pain after returning to the UK from a three-week trip to Nigeria. Infection with Plasmodium falciparum malaria was confirmed and treatment with quinine commenced together with amoxicillin/clavulanic acid and clarithromycin for possible respiratory infection. At the time of admission the patient could not remember the names of his ART medications. After 24 hours his parasitaemia had increased from 1% to 2.5% and his clinical condition had deteriorated. At this point, his ART was identified as abacavir, lamivudine and nevirapine. The Liverpool HIV-drug interactions website was checked for drug interactions. It recommends caution in the co-administration of both clarithromycin and quinine with nevirapine. Quinine is metabolized by CYP34A and exposure is likely to be decreased by induction of these enzymes in patients taking nevirapine. Given the clinical deterioration the patient was switched to Malarone® (atovoquone/ proguanil) which has no clinically significant interactions with nevirapine. He responded to treatment and was discharged home after 48 hours. This case highlights the importance of knowing the potential drug interactions with ART and the importance of checking for such interactions when prescribing new medications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22174067     DOI: 10.1258/ijsa.2009.009489

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  5 in total

1.  The effect of HIV on malaria in the context of the current standard of care for HIV-infected populations in Africa.

Authors:  Moses R Kamya; Pauline Byakika-Kibwika; Anne F Gasasira; Diane Havlir; Philip J Rosenthal; Grant Dorsey; Jane Achan
Journal:  Future Virol       Date:  2012       Impact factor: 1.831

2.  Impact of comorbidity on adverse drug reaction profile in a cohort of patients treated with Artemisinin combination therapies for uncomplicated malaria in Nigeria.

Authors:  Peter U Bassi; Adeline I Osakwe; Comfort K Ogar; Cassandra Elagbaje; Biyaya B Nwankwo; Sulayman T Balogun; Godwin N Ntadom; Ambrose O Isah
Journal:  Pharmacol Res Perspect       Date:  2017-03-24

3.  Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection.

Authors:  Kay Seden; Sara Gibbons; Catia Marzolini; Jonathan M Schapiro; David M Burger; David J Back; Saye H Khoo
Journal:  PLoS One       Date:  2017-03-23       Impact factor: 3.240

4.  Potential drug-drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria.

Authors:  Kazeem A Oshikoya; Ibrahim A Oreagba; Saheed Lawal; Olufunsho Awodele; Olayinka O Ogunleye; Idowu O Senbanjo; Sunday O Olayemi; Veronica C Ezeaka; Edamisan O Temiye; Titilope A Adeyemo; Oluranti Opanuga; Olufunmilayo A Lesi; Sulaimon A Akanmu
Journal:  HIV AIDS (Auckl)       Date:  2014-04-05

5.  Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity.

Authors:  Sanna R Rijpma; Jeroen J M W van den Heuvel; Maarten van der Velden; Robert W Sauerwein; Frans G M Russel; Jan B Koenderink
Journal:  Malar J       Date:  2014-09-13       Impact factor: 2.979

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.